Pulito Claudio, Sanli Toran, Rana Punam, Muti Paola, Blandino Giovanni, Strano Sabrina
Molecular Chemoprevention Group, Molecular Medicine Area, Regina Elena National Institute, Rome 00144, Italy.
Department of Oncology, Juravinski Cancer Center, McMaster University, Hamilton, ON L8V 5C2, Canada.
Metabolites. 2013 Nov 7;3(4):1051-75. doi: 10.3390/metabo3041051.
Cancer metabolism is the focus of intense research, which witnesses its key role in human tumors. Diabetic patients treated with metformin exhibit a reduced incidence of cancer and cancer-related mortality. This highlights the possibility that the tackling of metabolic alterations might also hold promising value for treating cancer patients. Here, we review the emerging role of metformin as a paradigmatic example of an old drug used worldwide to treat patients with type II diabetes which to date is gaining strong in vitro and in vivo anticancer activities to be included in clinical trials. Metformin is also becoming the focus of intense basic and clinical research on chemoprevention, thus suggesting that metabolic alteration is an early lesion along cancer transformation. Metabolic reprogramming might be a very efficient prevention strategy with a profound impact on public health worldwide.
癌症代谢是深入研究的焦点,这证明了其在人类肿瘤中的关键作用。接受二甲双胍治疗的糖尿病患者癌症发病率和癌症相关死亡率降低。这凸显了应对代谢改变可能对治疗癌症患者也具有潜在价值的可能性。在此,我们回顾二甲双胍作为一种在全球用于治疗II型糖尿病患者的老药的新作用,迄今为止它在体外和体内均展现出强大的抗癌活性,有望纳入临床试验。二甲双胍也正成为化学预防方面深入的基础和临床研究的焦点,这表明代谢改变是癌症转变过程中的早期病变。代谢重编程可能是一种非常有效的预防策略,对全球公共卫生具有深远影响。